{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"23.4","value":"2.8"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"30.3","value":"4.4"}]}]}],"denomUnitsSelected":"malignant lesions","denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"142"}],"units":"malignant lesions"}],"description":"Comparison of MSG and placebo 18F-DCFPyL tumour accumulation measured by the maximal standardized uptake values corrected for lean body mass (SULmax). For determination of tumour uptake, all malignant lesions, the SULmax were measured using the PET Edge tool running on MIM. All regions of interest were created in one dataset by a blinded observer, and then saved and compared to the identical location in the second dataset for matched comparisons of activity. The median SULmax in the malignant lesions will be used for this analysis.","dispersionType":"Full Range","groups":[{"description":"Participants who received MSG dissolved in juice, in a fasting state, prior to the administration of 18F-DCFPyL, in either the first or second PET/CT scan.","id":"OG000","title":"18F-DCFPyL PET/CT Scan With MSG Drink"},{"description":"Participants who received the Placebo juice, in a fasting state, prior to the administration of 18F-DCFPyL, in either the first or second PET/CT scan.","id":"OG001","title":"18F-DCFPyL PET/CT Scan With Placebo Drink"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one dose of each intervention and completed all study visits were included in the efficacy analysis.","reportingStatus":"POSTED","timeFrame":"scan with MSG and 3-7 days later, scan with Placebo (or vice versa)","title":"Tumour Maximal Standardized Uptake Values Corrected for Lean Body Mass (SULmax) for 18F-DCFPyL","type":"SECONDARY","typeUnitsAnalyzed":"malignant lesions","unitOfMeasure":"SULmax"}